Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Yoshinori Okuda, Seitaro Omoto, Takehito Taniura, Akira Shouzu & Shosaku Nomura. (2016) Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis. International Journal of General Medicine 9, pages 65-71.
Read now
Read now
Seitaro Omoto, Takehito Taniura, Tohru Nishizawa, Takeshi Tamaki, Akira Shouzu & Shosaku Nomura. (2015) Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 8, pages 339-345.
Read now
Read now
Anita Jagroop & Dimitri P Mikhailidis. (2015) Platelets and diabetes: A complex association. Platelets 26:3, pages 267-268.
Read now
Read now
Roberto Costante, Azzurra Stefanucci, Simone Carradori, Ettore Novellino & Adriano Mollica. (2015) DPP-4 inhibitors: a patent review (2012 – 2014). Expert Opinion on Therapeutic Patents 25:2, pages 209-236.
Read now
Read now
Michael H. Davidson. (2014) Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 56-65.
Read now
Read now
André J. Scheen. (2013) Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine 125:3, pages 7-20.
Read now
Read now
Articles from other publishers (36)
Federico Bernardini, Annunziata Nusca, Federica Coletti, Ylenia La Porta, Mariagrazia Piscione, Francesca Vespasiano, Fabio Mangiacapra, Elisabetta Ricottini, Rosetta Melfi, Ilaria Cavallari, Gian Paolo Ussia & Francesco Grigioni. (2023) Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease. Pharmaceutics 15:7, pages 1858.
Crossref
Crossref
Xinyuan Tan, She Chen, Liu He, Minling Huang & Xiaoshan Zhang. (2023) Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report. Anti-Cancer Drugs 34:6, pages 791-796.
Crossref
Crossref
Paulo Genestreti, Remo Furtado, Rocio Salsoso, Talia Dalçóquio, Andre Franci, Fernando Menezes, Cesar Caporrino, Aline Ferrari, Carlos Nakashima, Marco Scanavini Filho, Felipe Lima, Roberto Giraldez, Luciano Baracioli & Jose Nicolau. (2022) Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction. Journal of Clinical Medicine 11:19, pages 5776.
Crossref
Crossref
Bin Hu, Long Zhang, Zhang-Sheng Zhao, Yang-Cong Qi, Wei Zhou & You-Li Ma. (2022) The predictive value of Thromboelastography (TEG) parameters in vascular complications in patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications 36:8, pages 108236.
Crossref
Crossref
Antti Nätynki, Päivi Leisti, Jussi Tuusa, Outi Varpuluoma, Laura Huilaja, Kentaro Izumi, Sanna-Kaisa Herukka, Olavi Ukkola, Juhani Junttila, Nina Kokkonen & Kaisa Tasanen. (2022) Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients. Frontiers in Immunology 13.
Crossref
Crossref
Annunziata Nusca, Francesco Piccirillo, Federico Bernardini, Aurelio De Filippis, Federica Coletti, Fabio Mangiacapra, Elisabetta Ricottini, Rosetta Melfi, Paolo Gallo, Valeria Cammalleri, Nicola Napoli, Gian Paolo Ussia & Francesco Grigioni. (2022) Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. International Journal of Molecular Sciences 23:13, pages 7261.
Crossref
Crossref
Helen D. Berlie, Pramodini B. Kale-Pradhan, Tara Orzechowski & Linda A. Jaber. (2021) Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review. Annals of Pharmacotherapy 55:11, pages 1386-1396.
Crossref
Crossref
Annunziata Nusca, Dario Tuccinardi, Silvia Pieralice, Sara Giannone, Myriam Carpenito, Lavinia Monte, Mikiko Watanabe, Ilaria Cavallari, Ernesto Maddaloni, Gian Paolo Ussia, Silvia Manfrini & Francesco Grigioni. (2021) Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. Frontiers in Pharmacology 12.
Crossref
Crossref
Fu-Shun Yen, James Cheng-Chung Wei, Hei-Tung Yip, Chii-Min Hwu, Ming-Chih Hou & Chih-Cheng Hsu. (2021) Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan. Hepatology International 15:1, pages 179-190.
Crossref
Crossref
Li Xin, Shusen Sun, Jinwen Wang, Wenchao Lu, Tiansheng Wang & Huilin Tang. (2020) Dipeptidyl Peptidase 4 Inhibitors and Venous Thromboembolism Risk in Patients with Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials. Thrombosis and Haemostasis 121:01, pages 106-108.
Crossref
Crossref
Monica Verdoia, Patrizia Pergolini, Roberta Rolla, Claudia Ceccon, Marina Caputo, Gianluca Aimaretti, Harry Suryapranata & Giuseppe De Luca. (2018) Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy. Experimental and Clinical Endocrinology & Diabetes 129:01, pages 43-49.
Crossref
Crossref
Yi Li, Rong Li, Ziqian Feng, Qin Wan & Jianbo Wu. (2020) Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis. Frontiers in Pharmacology 11.
Crossref
Crossref
Yijie Yang, Hongdong Song, Bo Wang, Qi Tian & Bo Li. (2020) A novel di‐peptide Met‐Glu from collagen hydrolysates inhibits platelet aggregation and thrombus formation via regulation of Gq‐mediated signaling. Journal of Food Biochemistry 44:9.
Crossref
Crossref
Habib Yaribeygi, Stephen L. Atkin, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2020) A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:3, pages 328-334.
Crossref
Crossref
Marieke Sternkopf, Magdolna Nagy, Constance C.F.M.J. Baaten, Marijke J.E. Kuijpers, Bibian M.E. Tullemans, Julia Wirth, Wendy Theelen, Tom G. Mastenbroek, Michael Lehrke, Benjamin Winnerling, Lesley BaertsNikolaus Marx, Ingrid De MeesterYvonne DöringJudith M.E.M. Cosemans, Andreas DaiberSebastian StevenJoachim Jankowski, Johan W.M. Heemskerk & Heidi Noels. (2020) Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions. Arteriosclerosis, Thrombosis, and Vascular Biology 40:3.
Crossref
Crossref
Amélie I. S. Sobczak & Alan J. Stewart. (2019) Coagulatory Defects in Type-1 and Type-2 Diabetes. International Journal of Molecular Sciences 20:24, pages 6345.
Crossref
Crossref
Sebastian Steven, Katie Frenis, Matthias Oelze, Sanela Kalinovic, Marin Kuntic, Maria Teresa Bayo Jimenez, Ksenija Vujacic-Mirski, Johanna Helmstädter, Swenja Kröller-Schön, Thomas Münzel & Andreas Daiber. (2019) Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxidative Medicine and Cellular Longevity 2019, pages 1-26.
Crossref
Crossref
Anette Schulz, Olga D Chuquimia, Haris Antypas, Svava E Steiner, Ruben M Sandoval, George A Tanner, Bruce A Molitoris, Agneta Richter-Dahlfors & Keira Melican. (2018) Protective vascular coagulation in response to bacterial infection of the kidney is regulated by bacterial lipid A and host CD147. Pathogens and Disease 76:8.
Crossref
Crossref
Samah S. Abbas, Hesham M. Mahmoud, Mona F. Schaalan & Hanan S. El-Abhar. (2018) Involvement of brain natriuretic peptide signaling pathway in the cardioprotective action of sitagliptin. Pharmacological Reports 70:4, pages 720-729.
Crossref
Crossref
Yi Zhou, Zhiying Guo, Wenjing Yan & Wen Wang. (2018) Cardiovascular effects of sitagliptin - An anti-diabetes medicine. Clinical and Experimental Pharmacology and Physiology 45:7, pages 628-635.
Crossref
Crossref
Xiangjun Meng, Lanlan Cai, Tianming Ren, Dong Sun & Jingkai Gu. (2018) Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry. Analytical Methods 10:18, pages 2108-2114.
Crossref
Crossref
Md Motiur Rahman, Michael J. Scalese & Richard A. Hansen. (2017) Dipeptidyl Peptidase-4 Inhibitor–Associated Risk of Bleeding: An Evaluation of Reported Adverse Events. Annals of Pharmacotherapy 51:7, pages 563-569.
Crossref
Crossref
Sebastian Steven, Kerstin Jurk, Maximilian Kopp, Swenja Kröller-Schön, Yuliya Mikhed, Kathrin Schwierczek, Siyer Roohani, Fatemeh Kashani, Matthias Oelze, Thomas Klein, Sergey Tokalov, Sven Danckwardt, Susanne Strand, Philip Wenzel, Thomas Münzel & Andreas Daiber. (2017) Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. British Journal of Pharmacology 174:12, pages 1620-1632.
Crossref
Crossref
Tisha R Joy, Charles A McKenzie, Rommel G Tirona, Kelly Summers, Shannon Seney, Subrata Chakrabarti, Neel Malhotra & Melanie D Beaton. (2017) Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World Journal of Gastroenterology 23:1, pages 141.
Crossref
Crossref
Biplab Giri, Mrinmoy Sarkar & Sananda Dey. (2017) DOUBLE EDGE EFFECT OF DPP4 INHIBITOR SITAGLIPTIN, A TYPE-2 ANTI-DIABETIC DRUG, ON INFLAMMATION, INJURY AND CANCER. Journal of Stem cell & Regenerative Biology 3:1, pages 1-7.
Crossref
Crossref
Alison Cameron-Vendrig, Adili Reheman, M. Ahsan Siraj, Xiaohong Ruby Xu, Yiming Wang, Xi Lei, Talat Afroze, Eric Shikatani, Omar El-Mounayri, Hossein Noyan, Ralph Weissleder, Heyu Ni & Mansoor Husain. (2016) Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Diabetes 65:6, pages 1714-1723.
Crossref
Crossref
Tsutomu Hirano, Satoko Yamashita, Masaki Takahashi, Hiroyuki Hashimoto, Yusaku Mori & Moritaka Goto. (2016) Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits. Metabolism 65:6, pages 893-903.
Crossref
Crossref
Enzo Bonora & Massimo Cigolini. (2016) DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. Nutrition, Metabolism and Cardiovascular Diseases 26:4, pages 273-284.
Crossref
Crossref
Swati Jain & Bhupesh Sharma. (2015) Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. Physiology & Behavior 152, pages 182-193.
Crossref
Crossref
Athanasia Papazafiropoulou, Nikolaos Papanas, Stavros Pappas, Efstratios Maltezos & Dimitri P. Mikhailidis. (2015) Effects of oral hypoglycemic agents on platelet function. Journal of Diabetes and its Complications 29:6, pages 846-851.
Crossref
Crossref
Alison Cameron-Vendrig, Dhanwantee Mundil & Mansoor Husain. (2014) Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors. Current Atherosclerosis Reports 16:5.
Crossref
Crossref
Sandeep Dhindsa & Ishwarlal Jialal. (2014) Potential Anti-Atherosclerotic Effects of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus. Current Diabetes Reports 14:2.
Crossref
Crossref
Na-Hyung Kim, Taeyang Yu & Dae Ho Lee. (2014) The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors. BioMed Research International 2014, pages 1-10.
Crossref
Crossref
Yunjuan Zhao, Lin Yang & Zhiguang Zhou. (2014) Dipeptidyl peptidase-4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase -4抑制剂：多靶点药物，不仅仅是降糖药). Journal of Diabetes 6:1, pages 21-29.
Crossref
Crossref
B. Solun, D. Marcoviciu & D. Dicker. (2013) Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System. Current Cardiology Reports 15:8.
Crossref
Crossref
André J. Scheen. (2013) Cardiovascular effects of gliptins. Nature Reviews Cardiology 10:2, pages 73-84.
Crossref
Crossref